Genetics
Review concludes CETP's atherogenic effect depends on metabolic background, proposing it as a therapeutic target in hyperlipidemia (Curr Opin Lipidol 2000)
Original title: Cholesteryl ester transfer protein and atherosclerosis
This review surveys human plasma CETP research, focusing on the TaqIB, I405V, and D442G polymorphisms, addressing the debated significance of CETP in atherosclerosis across human population genetics and transgenic mouse studies. It concludes that CETP has a dual effect on atherosclerosis depending on the underlying metabolic background: in hypercholesterolemia or combined hyperlipidemia specifically, CETP may act as a pro-atherogenic factor and could represent a viable therapeutic target.
Original abstract
Plasma cholesteryl ester transfer protein facilitates the transfer of cholesteryl ester from HDL to apolipoprotein B-containing lipoproteins. Its significance in atherosclerosis has been debated in studies of human population genetics and transgenic mice. The current review will focus on human plasma cholesteryl ester transfer protein research, including TaqIB, 1405V, and D442G polymorphisms. Plasma cholesteryl ester transfer protein has a dual effect on atherosclerosis, depending on the metabolic background. In hypercholesterolaemia or combined hyperlipidaemia, plasma cholesteryl ester transfer protein may be pro-atherogenic and could be a therapeutic target.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.